But we’ll begin to see biosimilars and off-patent biological medicines being produced at significantly lower costs than their originator products, enabling the NHS to achieve savings of up to £300 million a year by 2021. Biologic drugs will create new opportunities for patient careĬurrently, 6 out of the 10 top medicines prescribed in UK hospitals are biological products used to treat a range of conditions, including cancer, rheumatoid arthritis and inflammatory bowel disease. This is the result of numerous factors, including increasing diagnostic applications of biomarkers, increasing number of CROs, the high prevalence of cancer, and new initiatives for biomarker research.ģ. ![]() According to the BioTech Pharma Summit, the biomarkers market is projected to reach $53 billion by 2021 from $27 billion in 2016. Precision medicine, and biomarkers in particular, are currently seeing substantial growth. “With the launch of Netspot last year and Novartis buying AAA for nearly $4 billion, we can anticipate a continuing development in this space with protein receptor radionuclide therapy (PRRT) and the corresponding theranostics” he added. “While it is difficult to make sweeping generalisations, I anticipate continuing development in the nuclear medicine and precision medicine arena,” observed Rob Johnson of Alacrita Consulting. More investment in nuclear medicine and precision medicine Expect to see more practical examples of how AI can be used this year.Ģ. 2018 won’t be the year we see AI taking responsibility for the end-to-end diagnosis-to-treatment cycles, but it’s certainly driving improved service offerings with every passing 12 months. It’s now expanding from back end capability to a far more sophisticated role: it’s transforming patience diagnosis and making clinical trials cheaper and faster, and it has the potential to transform regulatory information and submissions management. AI will continue to feature more heavilyĪrtificial Intelligence (AI) has been making waves in numerous industries (most notably in telecoms, financial services and marketing), and it would appear that the life sciences industry is no exception. So, how is 2018 looking to be shaping up? Here are five trend predictions for 2018 and beyond:ġ. But the change of recent times doesn’t mark the end of the story. We believe that the use of NETSPOT should also offer increased comfort for patients by potentially shortening a procedure that is currently performed over 24 hours or more to just a few hours.The life sciences and healthcare industries have been engaged in a digital transformation in recent years. “NETSPOT has the potential to significantly improve the accuracy of NET diagnosis, while reducing radiation exposure for patients. “The FDA approval of NETSPOT is a key milestone in our mission of improving the lives of NET patients,” said Stefano Buono, Chief Executive Officer of AAA. NETSPOT is currently approved for use with the GalliaPharm Ga 68 generator from Eckert & Ziegler. AAA intends to commercialize the product in the US in two forms: As a kit for reconstitution using a Ga 68 generator, and as NETSPOT Injection, a ready-to-use dose delivered from a local radiopharmacy in selected metropolitan areas. ![]() Gallium Ga 68 dotatate received Orphan Drug Designation from both the FDA and European Medicines Agency (EMA) in March 2014.įollowing today’s approval, NETSPOT will be made available to the US market as soon as possible. NETSPOT is the first approved drug using Ga 68 as a positron emitter. NETSPOT is the new market name for Somakit-TATE (a kit for the preparation of gallium Ga 68 dotatate injection) in the US. NETSPOT received approval following a Priority Review from the FDA. ![]() AAA today announced that the US Food and Drug Administration (FDA) has approved NETSPOT(TM) (Somakit-TATE) for the localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adult and pediatric patients.
0 Comments
Leave a Reply. |